Actuate Therapeutics Inc. (NASDAQ:ACTU) surged 14.41% to $2.46 in after-hours trading on Wednesday after Nature Medicine published Phase 2 pancreatic cancer trial data showing improved median overall survival with elraglusib plus gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone.
Elraglusib is a first-in-class, potent, small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β) that targets tumor survival pathways, reverses chemoresistance, and exhibits immunomodulatory properties.
What Is The Survival Benefit In Phase 2 Study
The randomized study in previously untreated metastatic pancreatic ductal adenocarcinoma reported median overall survival of 10.1 months versus 7.2 months in patients receiving gemcitabine and nab-paclitaxel alone, representing a 38% reduction in risk of death.
Daniel Schmitt, CEO of Actuate Therapeutics, said, “Elraglusib containing regimen delivered a 40% improvement in median overall survival, a 38% lower risk of death, and doubled the survival rate at one year compared to the current first-line chemotherapy regimen of …
